查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578213

全球急性激动和攻击性治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Acute Agitation And Aggression Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 231 Pages | 商品交期: 最快1-2个工作天内

价格

全球急性激动和攻击性治疗市场的需求预计将从 2023 年的 48.5 亿美元增至 2032 年的近 80.2 亿美元，2024-2032 年研究期间的复合年增长率为 5.75%。

急性激动是指伴随或不伴随异常运动活动的内在紧张或不安状态。而急性攻击性则意味着有可能自残或伤害他人的行为表现。急性激动和攻击性治疗只不过是为治癒患者的激动和攻击性而提供的医疗护理。一般来说，个体的急性躁动和攻击性是由于忧郁、躁郁症、酒精依赖、荷尔蒙失衡、自闭症、压力和神经系统疾病等原因引起的。急性躁动和攻击性治疗可以帮助恢復平静感。

市场动态

由于心理疾病中激动和攻击诊断的增加、心理疾病经济负担的增加以及传播意识的组织的形成，全球急性激动和攻击治疗市场越来越受欢迎。改变精神病患者对激动和攻击行为诊断的态度以及对治疗认识的提高可能会推动全球急性激动和攻击行为治疗市场的成长。此外，针对急性躁动和攻击性的新疗法的研究和开发预计将推动市场成长。精神疾病的增加、老年人口失智症发病率的增加、患者躁动的激增以及抗精神病药物处方的增加正在推动未来几年急性躁动和攻击性治疗市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球急性激动和攻击性治疗市场的各个细分市场进行了包容性评估。急性激动和攻击性治疗行业的成长和趋势为这项研究提供了整体方法。

市场区隔

急性激动和攻击性治疗市场报告的这一部分提供了有关国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人口统计数据以及即将到来的机会。

依治疗方法

  • 行为方法
  • 环境介入
  • 药理学方法（药物）（劳拉西泮、氯丙嗪、喹硫平、氟哌利多、奥氮平、齐拉西酮等）

按指示

  • 精神分裂症
  • 失智
  • 躁郁症
  • 沮丧
  • 药物引起的躁动和攻击性
  • 酒精戒断
  • 其他的

依给药途径

  • 口服
  • 肌肉注射
  • 其他的

按最终用户

  • 医院及门诊手术中心
  • 精神科护理设施
  • 其他的
  • 区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的全球急性激动和攻击性治疗市场报告市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。急性激动和攻击性治疗市场的主要参与者包括礼来公司、辉瑞公司、大冢控股、葛兰素史克、H. Lundbeck A/S、强生公司、梯瓦製药工业有限公司、Amneal Pharmaceuticals LLC、Sun Pharmaceutical Industries有限公司、F. Hoffmann-La Roche Ltd、Bausch Health Companies Inc.、Apotex Inc.、Aurobindo Pharma。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：急性激动与攻击行为治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 依处理法进行市场吸引力分析
    • 按指标进行的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球急性激动与攻击行为治疗市场分析：依治疗方法分类

  • 依治疗方法概述
  • 依处理方法进行历史和预测资料分析
  • 行为方法
  • 环境介入
  • 药理学方法（药物）（劳拉西泮、氯丙嗪、喹硫平、氟哌利多、奥氮平、齐拉西酮等）

第 6 章：全球急性激动与攻击行为治疗市场分析：依适应症分类

  • 按指示概述
  • 按指示进行历史和预测资料分析
  • 精神分裂症
  • 失智
  • 躁郁症
  • 沮丧
  • 药物引起的躁动和攻击性
  • 酒精戒断
  • 其他的

第 7 章：全球急性激动与攻击行为治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行历史和预测资料分析
  • 口服
  • 肌肉注射
  • 其他的

第 8 章：全球急性躁动与攻击性治疗市场分析：依最终使用者分类

  • 最终用户概述
  • 最终用户的历史和预测数据分析
  • 医院及门诊手术中心
  • 精神科护理设施
  • 其他的

第 9 章：全球急性躁动与攻击性治疗市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：急性激动与攻击行为治疗公司的竞争格局

  • 急性躁动和攻击性治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Eli Lilly And Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Otsuka Holdings
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GlaxoSmithKline
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • H. Lundbeck A/S
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Teva Pharmaceutical Industries Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Amneal Pharmaceuticals LLC
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sun Pharmaceutical Industries Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • F. Hoffmann-La Roche Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bausch Health Companies Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Apotex Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Aurobindo Pharma
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11218412

The global demand for Acute Agitation And Aggression Treatment Market is presumed to reach the market size of nearly USD 8.02 Billion by 2032 from USD 4.85 Billion in 2023 with a CAGR of 5.75% under the study period 2024-2032.

Acute Agitation refers to the state of inner tension or unease with or without abnormal motor activity. While acute aggression signifies a behavioural expression with the potential to self-harm or harm others. Acute agitation and aggressive treatment are nothing but the medical care given to a patient to get cured of agitation and aggression. Generally, acute agitation and aggression are caused in an individual due to reasons like depression, bipolar disorder, alcohol dependency, hormonal imbalances, autism, stress, and neurological disorders. Acute agitation and aggression treatment can help in restoring the sense of calm.

MARKET DYNAMICS

The global acute agitation and aggression treatment market is gaining popularity owing to the rise in the agitation and aggression diagnosis in psychological illnesses, the increase in the economic burden of psychological illness, and the formation of an organization to spread awareness. Altering attitudes toward agitation and aggression diagnosis among mentally ill patients and an increase in awareness about treatments are likely to fuel the global acute agitation and aggression treatment market growth. Additionally, research and development of novel treatments for acute agitation and aggression are expected to drive market growth. The rise in mental illness, increase in dementia incidences among the geriatric population, the rush in agitation in patients, and an increase in prescriptions of anti-psychotics are boosting the growth of the acute agitation and aggression treatment market in the forthcoming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Agitation And Aggression Treatment. The growth and trends of Acute Agitation And Aggression Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Agitation And Aggression Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Approach

  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others)

By Indication

  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation and Aggression
  • Alcohol Withdrawal
  • Others

By Route of Administration

  • Oral
  • Intramuscular
  • Others

By End User

  • Hospitals & Ambulatory Surgical Centers
  • Psychiatric Care Facilities
  • Others
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Global Acute Agitation And Aggression Treatment Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Agitation And Aggression Treatment market include Eli Lilly And Company, Pfizer Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ACUTE AGITATION AND AGGRESSION TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Approach
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By End User
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY TREATMENT APPROACH

  • 5.1. Overview By Treatment Approach
  • 5.2. Historical and Forecast Data Analysis By Treatment Approach
  • 5.3. Behavioral Approaches Historic and Forecast Sales By Regions
  • 5.4. Environmental Interventions Historic and Forecast Sales By Regions
  • 5.5. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Historic and Forecast Sales By Regions

6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data Analysis By Indication
  • 6.3. Schizophrenia Historic and Forecast Sales By Regions
  • 6.4. Dementia Historic and Forecast Sales By Regions
  • 6.5. Bipolar Disorder Historic and Forecast Sales By Regions
  • 6.6. Depression Historic and Forecast Sales By Regions
  • 6.7. Drug-induced Agitation and Aggression Historic and Forecast Sales By Regions
  • 6.8. Alcohol Withdrawal Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data Analysis By Route of Administration
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Intramuscular Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY END USER

  • 8.1. Overview By End User
  • 8.2. Historical and Forecast Data Analysis By End User
  • 8.3. Hospitals & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 8.4. Psychiatric Care Facilities Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACUTE AGITATION AND AGGRESSION TREATMENT COMPANIES

  • 10.1. Acute Agitation And Aggression Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Eli Lilly And Company
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Otsuka Holdings
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. GlaxoSmithKline
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. H. Lundbeck A/S
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Johnson & Johnson
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Teva Pharmaceutical Industries Ltd.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Amneal Pharmaceuticals LLC
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Sun Pharmaceutical Industries Ltd.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche Ltd
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Bausch Health Companies Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Apotex Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Aurobindo Pharma
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Acute Agitation And Aggression Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Acute Agitation And Aggression Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Acute Agitation And Aggression Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Approach
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.